(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.82% $ 7.05
Live Chart Being Loaded With Signals
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...
Stats | |
---|---|
Volumen de hoy | 892.00 |
Volumen promedio | 5 243.00 |
Capitalización de mercado | 1.65B |
EPS | $0 ( 2024-03-07 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-14 |
Last Dividend | $0.593 ( 2020-03-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | 7.66 |
ATR14 | $0 (0.00%) |
Bavarian Nordic A/S Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bavarian Nordic A/S Finanzas
Annual | 2023 |
Ingresos: | $7.06B |
Beneficio Bruto: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
Ingresos: | $7.06B |
Beneficio Bruto: | $4.52B (64.07 %) |
EPS: | $19.23 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Ingresos: | $3.15B |
Beneficio Bruto: | $1.70B (53.99 %) |
EPS: | $-4.93 |
Financial Reports:
No articles found.
Bavarian Nordic A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.593 | 2020-03-27 |
Last Dividend | $0.593 | 2020-03-27 |
Next Dividend | $0 | N/A |
Payout Date | 2020-04-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.593 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.27 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.34 | |
Div. Directional Score | 7.53 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VTKLY | Ex Dividend Knight | 2023-07-20 | Semi-Annually | 0 | 0.00% | |
LNVGY | Ex Dividend Knight | 2023-07-26 | Annually | 0 | 0.00% | |
CKHGY | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
SGPYY | Ex Dividend Knight | 2023-06-01 | Semi-Annually | 0 | 0.00% | |
GMVHY | Ex Dividend Junior | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
AILLO | Ex Dividend Knight | 2023-07-14 | Semi-Annually | 0 | 0.00% | |
NACB | Ex Dividend Junior | 2023-08-15 | Quarterly | 0 | 0.00% | |
CPKF | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
SZLMY | Ex Dividend Junior | 2023-05-03 | Annually | 0 | 0.00% | |
HONT | Ex Dividend Junior | 2023-08-14 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.209 | 1.500 | 5.82 | 8.74 | [0 - 0.5] |
returnOnAssetsTTM | 0.103 | 1.200 | 6.57 | 7.89 | [0 - 0.3] |
returnOnEquityTTM | 0.153 | 1.500 | 9.41 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.938 | 0.800 | 5.31 | 4.25 | [1 - 3] |
quickRatioTTM | 1.342 | 0.800 | 6.81 | 5.45 | [0.8 - 2.5] |
cashRatioTTM | 0.530 | 1.500 | 8.17 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00430 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 25.16 | 1.000 | 1.793 | 1.793 | [3 - 30] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.08 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00597 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.652 | 1.000 | 2.47 | 2.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.215 | 1.000 | 7.70 | 7.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 18.15 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.492 | 0.800 | -0.0521 | -0.0416 | [0.5 - 2] |
Total Score | 10.72 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 2.55 | 1.000 | 9.84 | 0 | [1 - 100] |
returnOnEquityTTM | 0.153 | 2.50 | 9.62 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.849 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 14.59 | 2.00 | 5.14 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00228 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.158 | 1.000 | 8.54 | 0 | [0.1 - 0.5] |
Total Score | 4.34 |
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico